Peregrine Pharmaceuticals PPHM disappears, falling 80% in premarket trading following the announcement of data discrepancies in Phase II testing of its bavituximab drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.